Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 7/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24538772 | 0.76 | CYP2A6 (0.42) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL244725 | 0.76 | ALDH1A1 (0.43) | CYP2A6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL9603309 | 0.76 | CYP2A6 (0.42) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL8224692 | 0.76 | CYP2A6 (0.42) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL13463395 | 0.76 | — | — | |
| SCHEMBL183214 | 0.76 | — | — | |
| SCHEMBL30704427 | 0.76 | — | — | |
| SCHEMBL20783618 | 0.74 | CYP2D6 (0.41) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| Hydrochloric Acid SCHEMBL25381774 | 0.73 | CYP2A6 (0.52) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL20783620 | 0.73 | CYP3A4 (0.44) | CYP2A6CYP2D6CYP2B6CYP2C19CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054408-B1 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | CYP2A6 544/4885CYP2D6 592/4885CYP2B6 490/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | CYP2A6 254/4885CYP2D6 241/4885CYP2B6 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.